Overview

Anastrazole Plus GnRH-agonist in the Treatment of Endometriosis Recurrence

Status:
Completed

Trial end date:
2015-07-01

Target enrollment:
0

Participant gender:
Female

Summary

The aromatase inhibitor (anastrazole) plus long acting GnRH agonist leuprolide acetate will be tested for the treatment of women with endometriosis recurrence compared with classical GnRH analog treatment. Pain symptom disappearance and disease free time during follow-up will be the outcomes for establishing which medical treatment is the best in endometriosis recurrence treatment.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Centre for Endocrinology and Reproductive Medicine, Italy

Treatments:

Anastrozole
Aromatase Inhibitors
Deslorelin
Leuprolide

Criteria

Inclusion Criteria:

- women affected by endometriosis showing recurrence of pain symptoms, previous surgery
for endometriosis

Exclusion Criteria:

- presence of other systemic diseases